Effects of α-methyl-para-tyrosine (AMPT) in drug-free depressed patients

Neuropsychopharmacology

Volumn 14, Issue 3, 1996, Pages 151-157

  Miller, Helen L ^a,b   Delgado, Pedro L ^a,b   Salomon, Ronald M ^a,b   Heninger, George R ^a,b,c   Charney, Dennis S ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c Yale University School of Medicine and the Connecticut Mental Health Center   (United States)

Author keywords

AMPT; Depressive disorder; Dopamine; Norepinephrine

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; DIPHENHYDRAMINE; DOPAMINE; HOMOVANILLIC ACID; METIROSINE; NORADRENALIN;

ADULT; ARTICLE; BEHAVIOR; CATECHOLAMINE BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MOOD; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029892087     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0893-133X(95)00072-L     Document Type: Article

References (29)

1. Avorn J, Everitt DE, Weiss S (1986): Increased antidepressant use in patients prescribed β-blockers. JAMA 255:357-360
2. Bacopoulos NG, Redmond DE, Roth RH (1979): Serotonin and dopamine metabolites in brain regions and cerebrospinal fluid of a primate species: Effects of ketamine and fluphenazine. J Neurochem 32:1215-1218
3. Bright RA, Everitt DE (1992): β-blockers and depression: Evidence against an association. JAMA 267:1783-1787
4. Brodie HKH, Murphy DL, Goodwin FK, Bunney WE Jr (1971): Catecholamines and mania: The effect of α-methyl-para-tyrosine on manic behavior and catecholamine metabolism. Clin Pharmacol Ther 112(2):218-224
5. Bunney WE Jr, Brodie KH, Murphy DL, Goodwin FK (1971): Studies of α-methyl-para-tyrosine, L-DOPA, and L-TRYPTOPHAN in depression and mania. Am J Psychiatry 127(7):872-881
6. Bunney WE Jr, Gershon ES, Murphy DL, Goodwin FK (1972): Psychobiologic and pharmacologic studies of manic-depressive illness. J Psychiatry Res 9:207-226
7. Bunney WE, Davis JM (1966): Norepinephrine in depressive reactions: A review. Arch Gen Psychiatry 13:483-494
8. Carney RM, Rich MW, Tevelde A, Saini J, Clark K, Freedland KE (1987): Prevalence of major depressive disorder in patients receiving beta blocker therapy versus other medications. Am J Med 83:223-226
9. Charney DS, Delgado PL (1992): Current concepts of serotonin neuronal function and the pathophysiology of depression. In Elliott M, Heal DJ, Marsden CA (eds), Experimental Approaches to Anxiety and Depression. London, John Wiley & Sons, Ltd
10. Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR (1990): Serotonin function and the mechanism of antidepressant action: Reversal of antidepressant induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 47:411-418
11. Delgado PL, Price LH, Miller HL, Salomon RM, Aghajanian GK, Heninger GR, Charney DS (1994): Serotonin and the neurobiology of depression: Effects of tryptophan depletion in drug-free depressed patients. Arch Gen Psychiatry 51:865-874
12. Delgado PL, Price LH, Heninger GR, Charney DS (1992): Neurochemistry of affective disorders. In Paykel ES (ed), Handbook of Affective Disorders. New York, Churchill Livingstone
13. Dimsdale JE, Newton RP, Joist T (1989): Neuropsychological side effects of beta blockers. Arch Intern Med 149:514-525
14. Engelman K, Horwitz D, Jequier E (1968): Biochemical and pharmacological effects of α-methyltyrosine in man. J Clin Invest 47:577-594
15. 2-adrenoreceptors in major affective disorder: Effect of long-term lithium carbonate treatment. Arch Gen Psychiatry 43:51-57
16. Goodwin FK, Murphy DL, Brodie KH, Bunney WE Jr (1970): L-DOPA, catecholamines, and behavior: A clinical and biochemical study in depressed patients. Biol Psychiatry 2:341-366
17. Kapur S, Mann JJ (1992): Role of the dopaminergic system in depression. Biol Psychiatry 32:1-17
18. Maas JW, Hattox SE, Landis DH, Roth RH (1976): The determination of a brain arteriovenous difference for 3-methoxy-4-hydroxyphenylethylene glycol (MHPG). Brain Res 118:167-173
19. 2 and β-adrenergic receptor binding in the frontal cortices of suicide victims. Arch Gen Psychiatry 43:954-959
20. Mazure C, Nelson C, Price LH (1986): Reliability and validity of the symptoms of major depressive illness. Arch Gen Psychiatry 43:451-156
21. Mendels J, Frazer A (1974): Brain biogenic amine depletion and mood. Arch Gen Psychiatry 30:447-451
22. Miller HL, Delgado PL, Salomon RM, Berman R, Krystal JH, Heninger GR, Charney DS (1995): The behavioral effects of catecholamine depletion on antidepressant induced remission of depression: Implications for monoamine hypothesis of antidepressant action. Arch Gen Psychiatry (in press)
23. Paykel ES, Fleminger R, Watson JP (1982): Psychiatric side effects of antihypertensive drugs other than reserpine. J Clin Psychopharmacol 2:14-39
24. Schildkraut JJ (1965): The catecholamine hypothesis of affective disorders: A review of supporting evidence. Am J Psychiatry 122:509-522
25. Siever LJ (1987): Role of noradrenergic mechanisms in the etiology of the affective disorders. In Meltzer HY (ed), Psychopharmacology: The Third Generation of Progress. New York, Raven
26. Siever LJ, Davis KL (1985): Overview: Toward a dysregulation hypothesis of depression. Am J Psychiatry 142:1017-1031
27. Sjoerdsma A, Engelman K, Spector S (1965): Inhibition of catecholamine synthesis in man with α-methyl-tyrosine, an inhibitor of tyrosine hydroxylase. Lancet 2:1092-1094
28. Thiesen BQ, Wallace SM, Blackburn JL, Wilson TW, Bergman UIF (1990): Increased prescribing of antidepressants subsequent to β-blocker therapy. Arch Intern Med 150: 2286-2290
29. Widerlov E, Lewander T (1978): Inhibition of the in vivo biosynthesis and changes of catecholamine levels in rat brain after α-methyl-p-tyrosine; time- and dose-response relationships. Naunyn-Schmiedeberg's Arch Pharmacol 304:111-123